Multiple stakeholders in the U.S. health care system are also paying closer attention than ever to the safety and efficacy of treatments and monitoring how pharmaceutical companies report the results of their clinical trials. A consequence of this scrutiny is the number of mass tort and product liability cases in which pharmaceutical companies’ analyses, interpretations and reporting of biologi...